Comprehensive Analysis of the Prognostic Values of the TRIM Family in Hepatocellular Carcinoma

被引:27
|
作者
Dai, Weiyu [1 ]
Wang, Jing [2 ]
Wang, Zhi [1 ]
Xiao, Yizhi [1 ]
Li, Jiaying [1 ]
Hong, Linjie [1 ]
Pei, Miaomiao [1 ]
Zhang, Jieming [1 ]
Yang, Ping [1 ]
Wu, Xiaosheng [1 ]
Tang, Weimei [1 ]
Jiang, Xiaoling [1 ]
Jiang, Ping [1 ]
Xiang, Li [3 ]
Li, Aimin [1 ]
Lin, Jianjiao [3 ]
Liu, Side [1 ,3 ]
Wang, Jide [1 ,3 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou, Peoples R China
[2] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Peoples R China
[3] Longgang Dist Peoples Hosp, Dept Gastroenterol, Shenzhen, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
基金
中国国家自然科学基金;
关键词
hepatocellular carcinoma; TRIM family; signature; prognosis; LASSO; POOR-PROGNOSIS; MESENCHYMAL TRANSITION; PROMOTES; CANCER; DEGRADATION; PROGRESSION; GENE; ENCYCLOPEDIA; CONTRIBUTES; EXPRESSION;
D O I
10.3389/fonc.2021.767644
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Accumulating studies have demonstrated the abnormal expressions and prognostic values of certain members of the tripartite motif (TRIM) family in diverse cancers. However, comprehensive prognostic values of the TRIM family in hepatocellular carcinoma (HCC) are yet to be clearly defined. Methods: The prognostic values of the TRIM family were evaluated by survival analysis and univariate Cox regression analysis based on gene expression data and clinical data of HCC from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The expression profiles, protein-protein interaction among the TRIM family, prediction of transcription factors (TFs) or miRNAs, genetic alterations, correlations with the hallmarks of cancer and immune infiltrates, and pathway enrichment analysis were explored by multiple public databases. Further, a TRIM family gene-based signature for predicting overall survival (OS) in HCC was built by using the least absolute shrinkage and selection operator (LASSO) regression. TCGA-Liver Hepatocellular Carcinoma (LIHC) cohort was used as the training set, and GSE76427 was used for external validation. Time-dependent receiver operating characteristic (ROC) and survival analysis were used to estimate the signature. Finally, a nomogram combining the TRIM family risk score and clinical parameters was established. Results: High expressions of TRIM family members including TRIM3, TRIM5, MID1, TRIM21, TRIM27, TRIM32, TRIM44, TRIM47, and TRIM72 were significantly associated with HCC patients' poor OS. A novel TRIM family gene-based signature (including TRIM5, MID1, TRIM21, TRIM32, TRIM44, and TRIM47) was built for OS prediction in HCC. ROC curves suggested the signature's good performance in OS prediction. HCC patients in the high-risk group had poorer OS than the low-risk patients based on the signature. A nomogram integrating the TRIM family risk score, age, and TNM stage was established. The ROC curves suggested that the signature presented better discrimination than the similar model without the TRIM family risk score. Conclusion: Our study identified the potential application values of the TRIM family for outcome prediction in HCC.
引用
收藏
页数:20
相关论文
共 50 条
  • [11] Identification of Hub Genes and Analysis of Prognostic Values in Hepatocellular Carcinoma by Bioinformatics Analysis
    Xu, Liangfei
    Tong, Tong
    Wang, Ziran
    Qiang, Yawen
    Ma, Fan
    Ma, Xiaoling
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2020, 359 (04) : 226 - 234
  • [12] Comprehensive Analysis of the Prognosis and Correlations With Immune Infiltration of S100 Protein Family Members in Hepatocellular Carcinoma
    Zheng, Susu
    Liu, Linxia
    Xue, Tongchun
    Jing, Chuyu
    Xu, Xin
    Wu, Yanfang
    Wang, Meixia
    Xie, Xiaoying
    Zhang, Boheng
    FRONTIERS IN GENETICS, 2021, 12
  • [13] Novel prognostic implications of YTH domain family 2 in resected hepatocellular carcinoma
    Nakagawa, Nobuhiko
    Sonohara, Fuminori
    Tanaka, Katsuhito
    Sunagawa, Yuki
    Inokawa, Yoshikuni
    Takami, Hideki
    Hayashi, Masamichi
    Yamada, Suguru
    Kanda, Mitsuro
    Tanaka, Chie
    Nakayama, Goro
    Koike, Masahiko
    Kodera, Yasuhiro
    ONCOLOGY LETTERS, 2021, 22 (01)
  • [14] Prognostic value of osteopontin in patients with hepatocellular carcinoma A systematic review and meta-analysis
    Sun, Tingting
    Li, Peng
    Sun, Diwen
    Bu, Qingao
    Li, Guoqiang
    MEDICINE, 2018, 97 (43)
  • [15] Comprehensive analysis of the prognostic and immunological signature of eight Tripartitemotif (TRIM) family molecules in human gliomas
    Lu, Jiajie
    Liang, Kairong
    Zou, Renheng
    Peng, Yuecheng
    Wang, Haojian
    Huang, Rihong
    Zeng, Zhaorong
    Feng, Zejia
    Fan, Yongyang
    Zhang, Shizhen
    Ji, Yunxiang
    Pang, Xiao
    Wang, Yezhong
    Zhang, Hongri
    Wang, Zhaotao
    AGING-US, 2023, 15 (12): : 5798 - 5825
  • [16] Prognostic significance of osteopontin in hepatocellular carcinoma: A meta-analysis
    Zhang, Chuan-Hai
    Xu, Ge-Liang
    Jia, Wei-Dong
    Ge, Yong-Sheng
    Li, Jian-Sheng
    Ma, Jin-Liang
    Ren, Wei-Hua
    INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (11) : 2685 - 2692
  • [17] Comprehensive Analysis of the Prognostic Significance of the TRIM Family in the Context of TP53 Mutations in Cancers
    Vu, Trung
    Fowler, Annaliese
    McCarty, Nami
    CANCERS, 2023, 15 (15)
  • [18] Integrated analysis of the functions and prognostic values of RNA binding proteins in hepatocellular carcinoma
    Wu, Zeng-Hong
    Huang, Hong-Ming
    Yang, Dong-Liang
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [19] Comprehensive analysis of potential prognostic genes for the construction of a competing endogenous RNA regulatory network in hepatocellular carcinoma
    Yue, Chaosen
    Ren, Yaoyao
    Ge, Hua
    Liang, Chaojie
    Xu, Yingchen
    Li, Guangming
    Wu, Jixiang
    ONCOTARGETS AND THERAPY, 2019, 12 : 561 - 576
  • [20] A Comprehensive Prognostic Analysis of POLD1 in Hepatocellular Carcinoma
    Hui Tang
    Tingting You
    Zhao Sun
    Chunmei Bai
    BMC Cancer, 22